Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]
News [2550]
Articles [106]
Editorials [3]
Conferences [84]
elearning [20]
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients...
Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )
6 Jun 2019
Understanding eligibility criteria for clinical trials to increase study size
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...
Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Expanded clinical trial inclusion criteria would double the percentage of...
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...
Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
Comment: The success of immunotherapy means we have to change our mindset as we...
Dr David Graham and Dr Edward B. Garon
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )
1 Jun 2019
Pembrolizumab is safe and effective and substantially increases overall...
Dr Edward B. Garon - UCLA, Los Angeles, USA
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
Cardiac events following radical radiotherapy for lung cancer
Dr Fei Sun - Leeds Cancer Centre, Leeds, UK
Cardiac events following radical radiotherapy for lung cancer ( Dr Fei Sun - Leeds Cancer Centre, Leeds, UK )
10 May 2019
ALK-positive NSCLC: Treatments and latest developments
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
ALK-positive NSCLC: Treatments and latest developments ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )
29 Apr 2019
ALK-positive NSCLC: Current landscape
Dr Antonio Passaro and Prof Rafal Dziadziuszko
ALK-positive NSCLC: Current landscape ( Dr Antonio Passaro and Prof Rafal Dziadziuszko )
29 Apr 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )
18 Apr 2019
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
Entrectinib in NTRK fusion-positive non-small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
18 Apr 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation